El Corte Inglés has delivered to the Spanish Association Against Cancer (AECC) a check for 197,275 euros for the research project on personalized immunotherapy. This amount comes from the proceeds from the campaign against breast cancer that El Corte Inglés organized last fall, on the occasion of the World Day Against Breast Cancer that is celebrated every October 19.
This new study is part of the agreement that the company has recently signed with the AECC, by which it undertakes to contribute one million euros in 5 years.
The research will focus on personalized immunotherapy and has an estimated duration of three years with two more extensions.. The project will be carried out by a multidisciplinary team from hospitals Clinic of Barcelona, Doce de Octubre (Madrid), Vall d’Hebron (Barcelona) and the University of Navarra, under the direction of Dr. Aleix Prat.
This new study, led by the doctor specializing in cancer medicine Aleix Prat, consists of activating the patients’ own immune system. To activate it, there are numerous approaches, from drugs to a more personalized treatment called Adoptive Cell Therapy or ACT. It is a type of immunotherapy that in its most general form consists of isolating the cells of the patient’s immune system and in the laboratory manipulate them and then return them to the patient through a transfusion to attack the cancer.
The presentation of this check, which will be used to finance the research project, was attended by, among others, Ramón Reyes, president of the Spanish Association Against Cancer (AECC), and the Director of Communication of El Corte Inglés, Ester Uriol.
Spanish Association Against Cancer
El Corte Inglés has been in close collaboration with the Spanish Association Against Cancer (AECC) for years, and The result of this is the joint project that they develop against breast cancer. It is an initiative that has evolved very positively and that has allowed the company to fund three research projects in their entirety so far.
The collaboration program betweene El Corte Inglés and the AECC to assist in breast cancer research started in 2014 with a project led by doctors Cristina Cruz and Judith Balmaña, the latter researcher Head of the Hereditary Cancer Genetics Group, at the Vall d’Hebron Institute of Oncology (VHIO). It focused on the investigation of new therapeutic alternatives to reduce the risk of relapse of hereditary breast cancer treated by surgery and chemotherapy.
For its part, the project of Dr. Violeta Serra, started in 2017 and which is also being developed at the VHIO in Barcelona, aims to design a predictive test that allows precision medicine, designed for each patient.
And in 2019 the doctor’s project was launched Gonzalo Millán from the Andalusian Center for Molecular Biology and Regenerative Medicine of Seville (CABIMER) and which deals with hormonal therapy, with an expected duration of four years. Its purpose is to analyze the role that a new tumor marker, recently discovered, plays in the hormonal signaling pathway in order to discover possible new therapeutic lines.
These types of actions are part of the policy of commitment to society that the company develops and that leads it to participate responsibly in different social, cultural, educational and sports activities.
– .
